TY - JOUR
TI - Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece
AU - Tzouvelekis, A.
AU - Karampitsakos, T.
AU - Gomatou, G.
AU - Bouros, E.
AU - Tzilas, V.
AU - Manali, E.
AU - Tomos, I.
AU - Trachalaki, A.
AU - Kolilekas, L.
AU - Korbila, I.
AU - Tomos, P.
AU - Chrysikos, S.
AU - Gaga, M.
AU - Daniil, Z.
AU - Bardaka, F.
AU - Papanikolaou, I.C.
AU - Euthymiou, C.
AU - Papakosta, D.
AU - Steiropoulos, P.
AU - Ntolios, P.
AU - Tringidou, R.
AU - Papiris, S.
AU - Antoniou, K.
AU - Bouros, D.
JO - Pulmonary Pharmacology and Therapeutics
PY - 2020
VL - 60
TODO - null
SP - null
PB - INSTAP Academic Press
SN - null
TODO - 10.1016/j.pupt.2019.101880
TODO - adenosquamous carcinoma;  aged;  Article;  cancer chemotherapy;  cancer growth;  cancer patient;  cancer surgery;  cancer survival;  current smoker;  disease association;  female;  fibrosing alveolitis;  forced vital capacity;  Greece;  human;  latent period;  lung adenocarcinoma;  lung cancer;  major clinical study;  male;  medical history;  multicenter study;  multimodality cancer therapy;  non small cell lung cancer;  population;  prevalence;  priority journal;  retrospective study;  risk factor;  sarcomatoid carcinoma;  small cell lung cancer;  squamous cell lung carcinoma;  adult;  clinical trial;  complication;  fibrosing alveolitis;  lung;  lung tumor;  middle aged;  mortality;  non small cell lung cancer;  pathology;  small cell lung cancer;  squamous cell carcinoma;  survival;  very elderly, Adult;  Aged;  Aged, 80 and over;  Carcinoma, Non-Small-Cell Lung;  Carcinoma, Squamous Cell;  Female;  Greece;  Humans;  Idiopathic Pulmonary Fibrosis;  Lung;  Lung Neoplasms;  Male;  Middle Aged;  Prevalence;  Retrospective Studies;  Risk Factors;  Small Cell Lung Carcinoma;  Survival
TODO - Background: Abundant evidence supports an association between Idiopathic Pulmonary Fibrosis (IPF) and lung cancer development. Data on diagnosis and management of patients with IPF and lung cancer are still scarce. Patients and methods: This was a retrospective multicenter study, enrolling 1016 patients with IPF from eight different centers between 2011 and 2018 in Greece. Our aim was to estimate prevalence of lung cancer in patients with IPF in Greece. Results: We identified 102 cases of patients with IPF and lung cancer (prevalence = 10.03% n = 102/1016, mean age±SD = 71.8 ± 6.9, 96 males, mean FVC±SD = 72.7 ± 19.7, mean DLCO±SD = 44.5 ± 16.3). We identified 85 cases (83.3%) of non-small cell lung cancer (35 squamous, 28 adenocarcinoma), and 15 cases (14.7%) of small cell lung cancer. Primary lesion was localized in lower lobes in 57.1% of cases. Lung cancer was diagnosed post IPF diagnosis (mean latency time + SD = 33.2 + 36.1 months) in 57.6% of patients and synchronously in 36.5% of patients. Chemotherapy was applied in 26.7% of cases, while 34.7% of patients underwent surgery. Median survival of patients with IPF and lung cancer was 27.4 months (95% CI: 20.6 to 36.8). Conclusions: IPF is a risk factor for lung cancer development. In line with current literature, squamous cell carcinoma is the most common histologic subtype in patients with IPF. Large randomized controlled studies on the management of patients with IPF and lung cancer are sorely needed. © 2019
ER -